To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road, which requires biotech company research. Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those companies fare financially is not just of interest to investors, but also should be on the radar screen of scientists and advocates too. Lately, stem cell companies have not …Read More
Osiris (OSIR)
The Australian stem cell biotech Mesoblast (MSB) has reportedly reached a deal with the American stem cell biotech Osiris (OSIR) to buy Osiris’ mesenchymal stem cell (MSC) unit. This is a big development in the MSC field. Osiris and Mesoblast are two major players in this particular subfield of the stem cell world so this deal, reportedly worth up to $100 million if specific milestones are reached in clinical trials in the future, will boost Mesoblast’s leadership in MSC-related clinical applications, although Mesoblast, led by …Read More